Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TERT | O14746 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27389163 | 0.98 | PPARG (0.48) | PPARGPPARAEP300TSHRTERT | |
| SCHEMBL5077214 | 0.98 | PPARG (0.48) | PPARGPPARAEP300TSHRTERT | |
| SCHEMBL128203 | 0.92 | — | — | |
| SCHEMBL126957 | 0.83 | PPARG (0.47) | PPARGPPARATERTPTPN1CYP1A2 | |
| SCHEMBL6002924 | 0.83 | PPARG (0.48) | PPARGPPARATERTPTPN1CYP1A2 | |
| SCHEMBL127073 | 0.81 | — | — | |
| SCHEMBL624501 | 0.81 | PPARG (0.56) | PPARGPPARATERTPTPN1CYP1A2 | |
| SCHEMBL1685059 | 0.81 | PPARG (0.56) | PPARGPPARATERTPTPN1CYP1A2 | |
| SCHEMBL5179598 | 0.81 | PPARG (0.56) | PPARGPPARATERTPTPN1CYP1A2 | |
| SCHEMBL5074175 | 0.81 | PPARG (0.50) | PPARGPPARATERTPTPN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11996445-B2 | Carbon nanotube composite, dispersion liquid using same, semiconductor device, method for producing semiconductor device, and wireless communication device and merchandise tag each using semiconductor device | TORAY INDUSTRIES, INC. (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20210328011-A1 | CARBON NANOTUBE COMPOSITE, DISPERSION LIQUID USING SAME, SEMICONDUCTOR DEVICE, METHOD FOR PRODUCING SEMICONDUCTOR DEVICE, AND WIRELESS COMMUNICATION DEVICE AND MERCHANDISE TAG EACH USING SEMICONDUCTOR DEVICE | TORAY INDUSTRIES, INC. (JP) | 2021-10-21 | — | — | US | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | PPARG 1888/4885PPARA 2203/4885EP300 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.